Awarded
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Absatz 8 SGB V zum Wirkstoff Ranibizumab, ATC S01LA04 für die Zeit 01.09.2024 - 31.08.2026
Track this recordWith Adjudera Pro, get alerted before a contract here runs out.
- Buyer
- DAK-Gesundheit
- Winners
- 1 0 1 Carefarm GmbH, 2care4 ApS, Aaragon Pharma s.r.o, Abacus Medicine A/S, Allomedic GmbH, axicorp Pharma B.V., Biogen GmbH, CC Pharma GmbH, EurimPharm Arzneimittel GmbH, Hexal AG, kohlpharma GmbH, Medicopharm AG, Novartis Pharma GmbH, Orifarm GmbH, Originalis B.V., ratiopharm GmbH, Samsung Bioepis NL B.V., STADApharm GmbH
- Contract value
- no value published
- Bids received
- 18
- Published
- 23 Sept 2026
- Awarded
- 1 Sept 2024
- Contract start
- 1 Sept 2024
- Contract end
- 2 Sept 2025estimated
- Region
- Hamburg